key: cord-0788539-ckony02h authors: Fink, S.; Ruoff, F.; Stahl, A.; Becker, M.; Kaiser, P.; Traenkle, B.; Junker, D.; Weise, F.; Ruetalo, N.; Hoerber, S.; Peter, A.; Nelde, A.; Walz, J.; Krause, G.; Schenke-Layland, K.; Joos, T.; Rothbauer, U.; Schneiderhan-Marra, N.; Schindler, M.; Templin, M. F. title: A throughput serological Western blot system using whole virus lysate for the concomitant detection of antibodies against SARS-CoV-2 and human endemic Coronaviridae date: 2020-08-04 journal: nan DOI: 10.1101/2020.07.31.20165019 sha: e9c3a6478dbe01c551e5027b279da109257446d9 doc_id: 788539 cord_uid: ckony02h BACKGROUND: Seroreactivity against human endemic coronaviruses has been linked to disease severity after SARS-CoV-2 infection. Assays that are capable of concomitantly detecting antibodies against endemic coronaviridae such as OC43, 229E, NL63, and SARS-CoV-2 may help to elucidate this question. We set up a platform for serum-screening and developed a bead-based Western blot system, namely DigiWest, capable of running hundreds of assays using microgram amounts of protein prepared directly from different viruses. METHODS: The parallelized and miniaturised DigiWest assay was adapted for detecting antibodies using whole protein extract prepared from isolated SARS-CoV-2 virus particles. After characterisation and optimization of the newly established test, whole virus lysates of OC43, 229E, and NL63 were integrated into the system. RESULTS: The DigiWest-based immunoassay system for detection of SARS-CoV-2 specific antibodies shows a sensitivity of 87.2 % and diagnostic specificity of 100 %. Concordance analysis with the SARS-CoV-2 immunoassays available by Roche, Siemens, and Euroimmun indicates a comparable assay performance (Cohen's Kappa ranging from 0.8799-0.9429). In the multiplexed assay, antibodies against the endemic coronaviruses OC43, 229E, and NL63 were detected, displaying a high incidence of seroreactivity against these coronaviruses. CONCLUSION: The DigiWest-based immunoassay, which uses authentic antigens from isolated virus particles, is capable of detecting individual serum responses against SARS-CoV-2 with high specificity and sensitivity in one multiplexed assay. It shows high concordance with other commercially available serologic assays. The DigiWest approach enables a concomitant detection of antibodies against different endemic coronaviruses and will help to elucidate the role of these possibly cross-reactive antibodies. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified beta coronavirus that crossed the species barrier and found its way into the human population in 2019. It causes the coronavirus disease 2019 (COVID- 19) , and the ongoing pandemic has a devastating effect on wide parts of the human population (1) . The virus is highly contagious causing the disease to spread very rapidly, yet symptoms of infected individuals vary widely. A fraction of COVID-19 patients develops a fatal course of the disease, while mild COVID-19 cases are frequently observed (2) . Different co-morbidity factors were recently identified, whereas the prediction of the course of the disease is not yet possible (3) . Protective antibodies formed after infection are associated with viral clearance, but the occurrence of high antibody titres has also been linked to more serious forms of the disease (4) . A role of pre-existing and cross-reacting antibodies, from endemic coronaviruses, that recognize proteins from SARS-CoV-2 is discussed and a phenomenon termed antibody-dependent enhancement (ADE), which is linked to existing antibodies, might be one of the reasons for life-threatening symptoms occurring during later stages of COVID-19 (5, 6 ). An assay capable of detecting antibodies against endemic coronaviridae, such as OC43, 229E, and NL63, will help to understand a possible role of existing antibodies against these human coronaviruses during COVID-19. Available systems are using recombinant antigens to detect viral protein-directed antibodies in serum or plasma samples. This approach is not only economical but also makes the generation of large reagent batches feasible, allowing for the generation of vast numbers of assays required for systematic patient screening (7, 8) . Here, we employ a novel way of building a serologic assay system to detect and characterise anti-SARS-CoV-2 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint antibodies. The approach utilised is based on the classical Western blot procedure, which has been modified to be run as a throughput assay system. The use of the complete pathogen proteome for antibody detection has been employed since the late 1970s (9) and subsequently proven to be useful for the identification of proteins recognized during the humoral immune response. In lysates, prepared from infectious virus particles, not only all possible viral proteins are present and can be probed in one assay, but the use of authentic antigens should enable the detection of antibodies recognising relevant protein modifications present in the naturally occurring pathogen. The DigiWest procedure, which is employed here, is a variant of the classical Western blot. It addresses the most obvious disadvantages of Western blotting, namely its low throughput, high antigen consumption and poor reproducibility. In the DigiWest, the assay signal is generated on microspheres rather than on a membrane, thus allowing the use of fast and standardised assay protocols on the Luminex platform. Due to the inbuilt possibility of multiplexing, multiple antigens from different viruses can be probed at the same time, enabling the set-up of semiquantitative seroreactivity screens. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. To prepare SARS-CoV-2 virus lysate, the supernatant of infected human Caco-2 cells was purified. Briefly, Caco-2 cells were infected 1:10 -1:500 with clinical isolate 200325_Tü1. 48 hours post infection the supernatant was collected, centrifuged and frozen. 900 µL of supernatant was added to 200 µL 20 % sucrose and centrifuged for 90 min at 4 °C and 14000 rpm. The supernatant was discarded and a PBS washing step was done, followed by another centrifugation step. The supernatant was discarded and the viral pellet was re-suspended in 25 µL of LDS sample buffer (Life Technologies) and heated for 5 min at 95 °C. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint Whole viral protein lysates from 229E, OC43, and NL63 (ZeptoMetrix Corp) and from SARS-CoV-2 were used for DigiWest as described. Briefly, viral protein lysates were used for gel electrophoresis and Western blotting using the NuPAGE system. Membranes were washed with PBST (0.1 % Tween-20, PBS) and membrane-bound proteins were biotinylated by adding 50 µM NHS-PEG12-Biotin (Thermo Fisher Scientific) in PBST for 1 h. After washing in PBST, membranes were dried overnight. Subsequently, the Western-Blot lanes were cut into 96 strips of 0.5 mm width and were transferred to a 96-well plate (Greiner Bio-One). For protein elution, 10 µL of elution buffer was added to each well (8 M urea, 1 % Triton-X100 in 100 mM Tris-HCl pH 9.5) The protein eluates were diluted with 90 µL dilution buffer (5 % BSA in PBST, 0.02% sodium azide). Neutravidin-coated MagPlex beads (Luminex) of a distinct colour ID were added to the protein eluates and binding was allowed overnight; 500 µM PEG12-biotin in PBST was added to block remaining Neutravidin binding sites. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint 1:200 in serum assay buffer; Dianova) was added and incubated for 45 min at 23 °C. The beads were washed twice with PBST and readout was performed on a Luminex FlexMAP 3D. The DigiWest analysis tool was used to assess serum reactivity against the viral proteins (10). Virus protein-specific peaks were identified and average fluorescence intensity (AFI) values were calculated by integration of peak areas. To detect the nucleocapsid of SARS-CoV-2 a commercial antibody was used (Sino Biologicals; 40143-R019). Incubation was performed as described previously (11) . Sensitivity and specificity for each assay were calculated using the results of the PCR-testing as the gold standard. Concordance was calculated using Cohen's Kappa with 95 % confidence intervals (CI) (12) . Correlation was calculated using Spearman´s r with 95 % CI. For determining the dynamic range, a sigmoidal, 4-parameter logistic regression was used to fit the data and interpolate the dilution factor at the cut-off signal. All statistical analyses were performed using GraphPad Prism 8 or R studio (version 1.3.959). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint The DigiWest procedure is a variation of the Western blot that brings this classical approach into significantly higher throughput (9) . Here, we used the method for size dependent separation of virus proteins reflecting the whole proteome and their subsequent immobilization on microspheres in order to adapt it to serum analysis. As a first step for detecting, serum antibodies recognizing viral proteins, lysates from infectious SARS-CoV-2 virus particles were prepared in SDS-PAGE loading buffer. DigiWest was performed as described using 0.5 µg of virus protein and Luminex microspheres sufficient to run 100 assays were generated. Detection of total protein on the loaded DigiWest beads (Fig. 1A) showed characteristic protein bands for the lysate. In the next step, human sera were diluted 1:200 in an optimized and modified serum assay buffer (see Materials and Methods) and incubated with the DigiWest microspheres. For SARS-CoV-2 negative samples, no or very low signals were obtained ( Fig. 1D) . High signals were detected from COVID-19 convalescent sera. Most sera showed their main peak of reactivity at 47 kDa, i.e. the size corresponding to the SARS-CoV-2 nucleocapsid protein (Fig. 1C) . Using an antibody generated against the SARS-CoV-2 nucleocapsid, a prominent peak at 47.2 kDa (Fig. 1B) was detected, which is consistent with the expected size of the protein. For a subset of serum samples, additional peaks corresponding to the spike protein are detected ( Fig. 1E) . Assay background was found to be variable, but since the determined signal intensities only consist of the peak area, reliable values were calculated using the DigiWest evaluation tool (10) . Since reactivity against the nucleocapsid protein is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint was consistently found in COVID-19 convalescent sera, these values were used for describing SARS-CoV-2 seroreactivity. To expand the assay and to cover human endemic coronaviruses, virus lysates from the two alpha coronaviruses 229E and NL63 and from the beta coronavirus OC43 were processed as described above, and equivalent DigiWest assays were established and combined into one assay system. When using sera from SARS-CoV-2 negative individuals, seroreactivity against viral proteins was found for a large fraction of tested samples. As for the SARS-CoV-2 DigiWest assay, the main serological activity for the different viruses was detected at a molecular weight that corresponds to nucleocapsid proteins. To prove that the detected proteins are indeed the nucleocapsids of the different coronaviruses, we produced recombinant versions of the nucleocapsid proteins of all tested viruses. We used the purified proteins in a different DigiWest experiment and compared the obtained signals with the signals obtained from the whole virus lysate DigiWest ( Fig. 2A) . In the whole virus lysate, the observed molecular weight of SARS-CoV-2 nucleocapsid protein was 47.2 kDa with a calculated molecular weight of 45.6 kDa, for OC43 nucleocapsid protein it was is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint To characterize the performance of the DigiWest, we used the final multiplexed assay now comprising virus lysates of SARS-CoV-2, 229E, OC43 and NL63 to screen a set of characterized samples (13) . Among the analyzed sera, there were To demonstrate the dynamic range of the serologic DigiWest assay, a SARS-CoV-2 positive serum was serially diluted with a negative serum (Fig. 3) . Good signal linearity was seen in the dilution curve and seropositivity was detected down to a serum dilution of 1:5000. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. Correlation analysis utilizing Spearman´s r revealed a positive correlation of all investigated assays (Fig. 4D) . The highest correlation for DigiWest was found with is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint were compared based on the SARS-CoV-2 PCR status. The determined values for all employed systems are listed in Table 1 . By integrating DigiWest assays for 229E, OC43 and NL63 into the detection system showed values ranging from 0.03 to 0.75 (Fig. 5) . The highest correlation was observed for antibodies recognizing the nucleocapsid protein of 229E and NL63 with a Spearman´s r of 0.75 indicating a possible cross-reactivity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint The use of authentic proteins from clinically relevant pathogens as antigens for antibody detection is a classical method for identifying an individual immune response (17) . While the approach has distinct drawbacks, e. g. the need for isolation of large amounts of pathogen and poor assay reproducibility when using different protein batches, it also provides substantial advantages. Modifications only found in the authentic proteins are present in antigen preparations and therefore the identification of reactive antibodies against these possible pathogen-derived antigens should be feasible. In addition, the generation of protein extract from pathogens of different strains is often technically uncomplicated and fast. This may turn out to be especially useful when a comparative analysis of antigen preparations from closely related pathogenic agents is of interest. Such an analysis may facilitate the identification of relevant cross-reacting antibodies directly on a wide variety of antigenic structures. These advantages may help to set up systems that take an unbiased approach to characterising the humoral immune response and may allow the identification of cross-reacting antibodies. Here we describe the set-up of such an assay system using protein extracts prepared directly from infectious SARS-CoV-2 virus particles. The employed DigiWest procedure is an immunoblot system that closely resembles the classical Western blot procedure. After SDS-PAGE based protein size separation, proteins are immobilized on polystyrene microspheres and assay read-out is performed on the Luminex assay platform. 10 micrograms of protein are sufficient to generate batches of assay material for thousands of serum analyses; this directly translates into good assay reproducibility. In addition, the use of the Luminex platform for read-out allows for a high assay throughput without the need for producing recombinant proteins. As is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint in Western blotting, the assay gives direct information on the size of the recognized proteins, and often antigenic proteins can be directly identified. When using COVID-19 convalescent sera, a specific antibody response to a protein of 47 kDa corresponding to the nucleocapsid protein of SARS-CoV-2 was recurrently seen. Reactivity against other viral proteins was present in individual serum samples, yet the nucleocapsid protein was identified as the major antigen in this assay. The observed low seroreactivity against the spike protein is due to the fact that reduced and denatured proteins were employed for the DigiWest and that these protein forms are not recognized by most of the anti-spike antibodies (data not shown). For the detailed evaluation of the performance of the newly developed assay for detecting anti SARS-CoV-2 antibodies a set of more than 250 well-characterized sera was employed, which were mainly taken from a clinical study on T-cell response after SARS-CoV-2 infection (13) . By using 4 different serological assays that are in use in clinical routine labs we showed high concordance (Cohen's Kappa 0.88-0.94) between all systems. The detected specificity as compared to the PCR results was found to be ranging from 85.5 % to 100 %, with the DigiWest, the Roche and the Siemens systems approaching 100 %. Sensitivity was found between 76.4 % and 87.2 %, with the DigiWest reaching the highest score here. This demonstrates high standards for all tested assays. Interestingly, the highest concordance (0.94) was found between the Siemens assay system and the Euroimmun IgG assay, with both assays mainly detecting the spike protein. Nearly the same Kappa value was calculated for the Roche and the DigiWest system, both of which use the nucleocapsid protein as the detected antigen. The Euroimmun IgA showed slightly different assay characteristics, which is most likely due to the fact that it is the only is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint assay that exclusively detects IgA immunoglobulins. Yet, no principle differences in assay characteristics were observed and all assays showed high quality. Antibodies against endemic coronaviruses are frequently found in human individuals (18) . These viruses cause mild diseases and are associated with approximately 20 % of the common colds (19, 20) . However, when comparing the sequences of the virus genome, the degree of similarity between the SARS-CoV-2 and these viruses is astonishingly high (21) . This similarity has led to speculations that antibodies against these endemic viruses may also possess protective properties against SARV-CoV-2 (22) . The presence of these antibodies might explain the vastly diverse courses of disease. Therefore, the DigiWest assay system was expanded by using lysates from alpha coronaviruses 229E and NL63 as well as the beta coronaviruses OC43, thus enabling the detection of serum antibodies recognizing antigens from these four coronaviruses from one specimen in one assay. The implementation of these assays directly followed the method used for SARS-CoV-2 and seroreactivity against the nucleocapsid protein was frequently found for these coronaviruses. As expected a very high rate of infection for all of the coronaviruses was found, yet no indication of cross-reactivity to the SARS-CoV-2 proteins was seen in prepandemic and other SARS-CoV-2 negative samples. This is in contrast to the described T-cell response that can be triggered by peptides derived from the SARS-CoV-2 nucleocapsid (13,23). Since the described assay was optimized for specificity, the employed assay conditions were highly stringent to avoid the occurrence of false positive signals. Modifications of the assay that use less stringent conditions assays could be used to detect cross-reactivity of antibodies formed against proteins from endemic . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint coronaviruses to SARS-CoV-2 viral proteins. This could give valuable information on the nature of these frequently found anti-corona antibodies; this work is ongoing. As a serologic assay system the use of the DigiWest approach is not only novel, but it allows the set-up of a highly specific assay within a very short time frame and it is capable of detecting a wide variety of serum antibodies since all pathogen-derived proteins can be probed in one reaction. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20165019 doi: medRxiv preprint Supplemental Material is available online. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. indicating cross-reactivity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. 232 229 228 226 231 236 239 243 242 242 243 243 238 233 218 202 222 241 242 243 245 248 246 245 247 248 247 247 247 247 247 246 248 249 247 245 246 247 247 248 247 247 247 246 245 245 246 247 247 247 246 244 244 245 244 244 245 245 245 245 246 246 246 245 245 244 245 246 245 244 246 247 248 249 249 250 249 249 247 246 246 246 247 247 248 250 249 249 247 246 247 248 248 248 247 247 247 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 4, 2020. A new coronavirus associated with human respiratory disease in China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link? Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections A perspective on potential antibody-dependent enhancement of SARS-CoV-2 Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect A serological assay to detect SARS-CoV-2 seroconversion in humans Western Blotting": Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A A bead-based western for high-throughput cellular signal transduction analyses Arraybased Western-blotting reveals spatial differences in hepatic signaling and metabolism following CAR activation Lessons in biostatistics interrater reliability : the kappa statistic -2 T-cell epitopes define heterologous and COVID-19-induced Tcell recognition Clinical Performance of Two SARS-CoV-2 Serologic Assays Clinical Performance of the Roche SARS-CoV-2 Serologic Assay Evaluation of three fully-automated SARS-CoV-2 Antibody Response of Patients with Severe Acute Respiratory Syndrome (SARS) Targets the Viral Nucleocapsid Lessons for COVID-19 immunity from other coronavirus infections Epidemiology and Clinical Symptoms Related to Seasonal Coronavirus Identified in Patients with Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China Epidemiology of Seasonal Coronaviruses: Establishing the Context for the Emergence of Coronavirus Disease Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals